Dr. Bellmunt on JAVELIN Bladder 100 data for maintenance avelumab in urothelial carcinoma
The initial results from JAVELIN Bladder 100 supported the FDA approval of avelumab for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma.
Joaquim Bellmunt, MD, PhD, discusses the latest update on the phase 3 JAVELIN Bladder 100 trial (NCT02603432), in which frontline maintenance avelumab (Bavencio) and best supportive care (BSC) significantly prolonged overall survival vs BSC alone in patients with advanced urothelial carcinoma who had not progressed with first-line platinum-containing chemotherapy.
The initial results from JAVELIN Bladder 100 supported the FDA approval of avelumab for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.
Bellmunt is associate professor of medicine at Harvard Medical School and director of the Bladder Cancer Program at Beth Israel Deaconess Medical Center in Boston, Massachusetts.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.
